NATURES SUNSHINE Q3 Sales Jump, Net Income Nearly Doubles YTD

TL;DR

**NATR is crushing it with sales and profit growth, and consolidating joint ventures is a smart play for future market dominance.**

AI Summary

NATURES SUNSHINE PRODUCTS INC (NATR) reported a strong financial performance for the three and nine months ended September 30, 2025. Net sales for the three-month period increased by 11.98% to $128.339 million from $114.615 million in the prior year, while net sales for the nine-month period rose by 5.99% to $356.337 million from $336.159 million. Gross profit saw a significant increase of 15.03% to $94.049 million for the three months and 7.65% to $257.945 million for the nine months. Net income attributable to common shareholders surged by 22.69% to $5.334 million for the quarter and by 92.26% to $15.414 million for the nine-month period. Basic earnings per share increased to $0.30 from $0.23 for the quarter and to $0.85 from $0.43 for the nine months. The company also repurchased $14.376 million of common stock during the nine months ended September 30, 2025, compared to $8.436 million in the prior year. A key business change involves the planned purchase of Fosun Industrial's interests in two joint ventures, Nature's Sunshine Hong Kong Limited and Shanghai Nature's Sunshine Health Products Co., Ltd., for a total of $7.0 million, following Fosun Pharma ceasing to own at least 5% of NATR's common stock.

Why It Matters

NATR's robust sales growth and significant net income increase demonstrate strong operational execution and market demand for its health and wellness products, which is a positive signal for investors. The planned acquisition of Fosun Industrial's joint venture interests for $7.0 million will consolidate ownership, potentially streamlining operations and increasing future profitability, enhancing competitive positioning in key Asian markets. This move could also impact employees in the joint ventures through integration efforts and offers customers a more unified brand experience. The broader market for nutritional supplements continues to show resilience, and NATR's performance suggests it is capturing a growing share, putting pressure on competitors.

Risk Assessment

Risk Level: medium — While NATR shows strong financial performance, the company faces significant risks including extensive government regulations in foreign markets, potential legal challenges to its direct selling model, and the inherent volatility of foreign exchange rates, as evidenced by a foreign currency translation loss of $1.404 million for the three months ended September 30, 2025. The reliance on independent consultants also presents a risk if the company fails to attract and retain them.

Analyst Insight

Investors should consider NATR's strong financial performance and strategic consolidation of joint ventures as a positive indicator. The increased net income and EPS, coupled with share repurchases, suggest a company committed to shareholder value. Monitor the successful completion of the joint venture acquisitions and ongoing regulatory compliance, especially in international markets, as these are key to sustained growth.

Financial Highlights

debt To Equity

0.59

revenue

$128.339M

operating Margin

7.0%

total Assets

$264.805M

total Debt

$57.405M

net Income

$5.334M

eps

$0.30

gross Margin

73.3%

cash Position

$95.554M

revenue Growth

+11.98%

Revenue Breakdown

Key Numbers

• $128.339M — Net Sales (Q3 2025) (Increased 11.98% from $114.615M in Q3 2024)
• $356.337M — Net Sales (YTD 2025) (Increased 5.99% from $336.159M in YTD 2024)
• $5.334M — Net Income (Q3 2025) (Increased 22.69% from $4.347M in Q3 2024)
• $15.414M — Net Income (YTD 2025) (Increased 92.26% from $8.017M in YTD 2024)
• $0.30 — Basic EPS (Q3 2025) (Increased from $0.23 in Q3 2024)
• $0.85 — Basic EPS (YTD 2025) (Increased from $0.43 in YTD 2024)
• $14.376M — Common Stock Repurchases (YTD 2025) (Increased from $8.436M in YTD 2024)
• $7.0M — Joint Venture Acquisition Cost (Total cash consideration for Fosun Industrial's interests)
• $95.554M — Cash and Cash Equivalents (Sept 30, 2025) (Increased from $84.700M at Dec 31, 2024)
• 17,495,563 — Shares Outstanding (Oct 24, 2025) (Reflects share repurchases)

Key Players & Entities

• NATURES SUNSHINE PRODUCTS INC (company) — Registrant
• Fosun Pharma (company) — Former significant shareholder and joint venture partner
• Fosun Industrial Co., Ltd. (company) — Affiliate of Fosun Pharma, selling joint venture interests
• Nature's Sunshine Hong Kong Limited (company) — Joint venture being acquired by NATR
• Shanghai Nature's Sunshine Health Products Co., Ltd. (company) — Joint venture being acquired by NATR
• $128.339 million (dollar_amount) — Net sales for three months ended September 30, 2025
• $356.337 million (dollar_amount) — Net sales for nine months ended September 30, 2025
• $5.334 million (dollar_amount) — Net income attributable to common shareholders for three months ended September 30, 2025
• $15.414 million (dollar_amount) — Net income attributable to common shareholders for nine months ended September 30, 2025
• $14.376 million (dollar_amount) — Common stock repurchases for nine months ended September 30, 2025

FAQ

Risk Factors

• Extensive Government Regulations [high — regulatory]: The company's products, business practices, and manufacturing activities are subject to extensive government regulations, including trade restrictions and export controls. Compliance with these regulations is critical for market access and operational continuity.
• Direct Selling Program Legal Challenges [high — regulatory]: Potential legal challenges to the company's direct selling program or the classification of its independent consultants pose a significant risk. Laws and regulations regarding direct selling may restrict sales or necessitate business model changes.
• Reliance on Independent Consultants [medium — operational]: The company's ability to attract and retain independent consultants is crucial. The loss of key consultants or liabilities arising from improper consultant activity could negatively impact sales and operations.
• Product Liability Claims [medium — legal]: The company faces the risk of product liability claims, which could result in significant financial and reputational damage. Ensuring product safety and quality is paramount.
• Foreign Market Entry and Compliance [medium — regulatory]: Registering products for sale in foreign markets, or difficulties and increased costs associated with importing products, present ongoing challenges. Compliance with diverse international regulations is essential.
• Anti-Bribery Law Compliance [medium — legal]: Adherence to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act, is critical. Non-compliance can lead to severe penalties and reputational harm.

Industry Context

Nature's Sunshine Products operates in the highly competitive health and wellness industry, characterized by direct selling models. Key trends include increasing consumer demand for natural and scientifically-backed supplements, alongside evolving regulatory landscapes globally. The direct selling channel relies heavily on independent consultant networks, making distributor engagement and compliance critical success factors.

Regulatory Implications

The company faces significant regulatory scrutiny related to product claims, manufacturing standards, and the classification of its independent sales force. Compliance with international trade regulations, direct selling laws, and anti-bribery statutes is essential to avoid operational disruptions and legal penalties.

What Investors Should Do

1. Monitor Joint Venture Acquisition Impact
2. Evaluate Share Repurchase Strategy
3. Analyze Margin Trends
4. Assess Growth Drivers

Key Dates

• 2025-09-30: End of Third Quarter and Nine Months — Reporting period for strong net sales growth (11.98% Q3, 5.99% YTD) and significant net income increase (22.69% Q3, 92.26% YTD).
• 2025-10-24: Shares Outstanding Date — 17,495,563 shares outstanding, reflecting the impact of ongoing share repurchase programs.
• 2024-12-31: End of Fiscal Year 2024 — Reference point for balance sheet comparison, showing an increase in cash and cash equivalents from $84.700M to $95.554M.

Glossary

Net Sales

The total revenue generated from sales of products and services after deducting returns, allowances, and discounts. (Key indicator of top-line performance and market demand for Nature's Sunshine's products.)

Gross Profit

The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. (Measures the efficiency of production and pricing strategies. A significant increase indicates improved cost management or pricing power.)

Basic Earnings Per Share (EPS)

The portion of a company's profit allocated to each outstanding share of common stock, calculated by dividing net income by the weighted-average number of outstanding common shares. (A fundamental measure of profitability on a per-share basis, directly impacting shareholder value.)

Noncontrolling Interest

The portion of equity ownership in a subsidiary that is not attributable to the parent company. (Represents the ownership stake of external shareholders in consolidated subsidiaries, impacting the net income attributable to common shareholders.)

Operating Lease Right-of-Use Assets

Assets recognized under accounting standards for leases, representing the right to use an asset for the lease term. (Reflects the company's long-term rental commitments for properties or equipment.)

Volume Incentives

Payments or discounts provided to distributors or consultants based on the volume of sales they achieve. (A significant operating expense in direct selling models, directly tied to sales performance and distributor compensation.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Nature's Sunshine Products Inc. demonstrates robust growth. Net sales for the three months ended September 30, 2025, increased by 11.98%, and year-to-date sales grew by 5.99%. Gross profit also saw substantial increases, indicating improved operational efficiency or pricing power. Net income attributable to common shareholders surged significantly, up 22.69% for the quarter and an impressive 92.26% year-to-date, leading to a notable rise in basic EPS. The company also increased its share repurchase activity, signaling confidence and a commitment to shareholder returns.

Filing Documents

• natr-20250930.htm (10-Q) — 1247KB
• natr2025930-ex103.htm (EX-10.3) — 149KB
• natr2025930-ex311.htm (EX-31.1) — 14KB
• natr2025930-ex312.htm (EX-31.2) — 14KB
• natr2025930-ex313.htm (EX-31.3) — 14KB
• natr2025930-ex321.htm (EX-32.1) — 6KB
• natr2025930-ex322.htm (EX-32.2) — 6KB
• natr2025930-ex323.htm (EX-32.3) — 6KB
• natr-20250930_g1.jpg (GRAPHIC) — 115KB
• 0000275053-25-000004.txt ( ) — 6650KB
• natr-20250930.xsd (EX-101.SCH) — 30KB
• natr-20250930_cal.xml (EX-101.CAL) — 56KB
• natr-20250930_def.xml (EX-101.DEF) — 136KB
• natr-20250930_lab.xml (EX-101.LAB) — 510KB
• natr-20250930_pre.xml (EX-101.PRE) — 323KB
• natr-20250930_htm.xml (XML) — 1031KB

Financial Information

Part I. Financial Information 4 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of I ncome 5 Condensed Consolidated Statements of Comprehensive Incom e 7 Condensed Consolidated Statement s of Changes in Shareholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31

Other Information

Part II. Other Information 32 Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 34 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain information included or incorporated herein by reference in this report may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvement in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. For example, information appearing under "Management's Discussion and Analysis of Financial Condition and Results of Operations" includes forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under "Risk Factors" in Item 1A, and in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, but

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

Item 1. FINANCIAL STATEMENTS NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 95,554 $ 84,700 Accounts receivable, net of allowance for doubtful accounts of $ 66 and $ 97 , respectively 15,114 9,477 Inventories 67,335 59,443 Prepaid expenses and other 8,081 6,959 Total current assets 186,084 160,579 Property, plant and equipment, net 33,972 39,585 Operating lease right-of-use assets 12,963 12,799 Restricted investment securities - trading 1,107 915 Deferred income tax assets 20,360 17,644 Other assets 10,319 9,333 Total assets $ 264,805 $ 240,855 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 7,119 $ 8,912 Accrued volume incentives and service fees 25,387 20,563 Accrued liabilities 31,407 25,399 Deferred revenue 7,536 2,774 Income taxes payable 7,599 4,117 Current portion of operating lease liabilities 4,601 3,927 Total current liabilities 83,649 65,692 Liability related to unrecognized tax benefits 444 628 Long-term portion of operating lease liabilities 9,687 10,277 Deferred compensation payable 1,107 915 Deferred income tax liabilities 1,075 1,007 Other liabilities 2,139 1,345 Total liabilities 98,101 79,864 Shareholders' equity: Common stock, no par value, 50,000 shares authorized, 17,560 and 18,483 shares issued and outstanding, respectively 103,553 114,577 Retained earnings 72,821 57,407 Noncontrolling interest 6,202 5,678 Accumulated other comprehensive loss ( 15,872 ) ( 16,671 ) Total shareholders' equity 166,704 160,991 Total liabilities and shareholders' equity $ 264,805 $ 240,855 See accompanying notes to condensed consolidated financial statements. 4 Table of Contents NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Amounts in thousands, except per share infor

View Full Filing

View this 10-Q filing on SEC EDGAR